Vaccinex, Inc. (VCNX)
USD 1.0
(66.67%)
USD 1.0
(66.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 23.45 Million USD | 16.65% |
| 2022 | 20 Million USD | -14.47% |
| 2021 | 23.39 Million USD | -17.58% |
| 2020 | 28.37 Million USD | -12.25% |
| 2019 | 32.33 Million USD | 19.9% |
| 2018 | 26.97 Million USD | 28.23% |
| 2017 | 21.03 Million USD | 2.81% |
| 2016 | 20.46 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.17 Million USD | 4.36% |
| 2024 Q2 | 5.92 Million USD | 14.99% |
| 2023 FY | 23.33 Million USD | 16.65% |
| 2023 Q1 | 5.53 Million USD | 7.1% |
| 2023 Q4 | 4.96 Million USD | -15.25% |
| 2023 Q2 | 7.07 Million USD | 27.84% |
| 2023 Q3 | 5.85 Million USD | -17.28% |
| 2022 Q3 | 4.84 Million USD | -10.35% |
| 2022 FY | 20 Million USD | -14.47% |
| 2022 Q1 | 4.59 Million USD | -16.75% |
| 2022 Q2 | 5.4 Million USD | 17.57% |
| 2022 Q4 | 5.16 Million USD | 6.75% |
| 2021 Q2 | 5.66 Million USD | -20.04% |
| 2021 Q1 | 7.09 Million USD | 16.44% |
| 2021 FY | 23.39 Million USD | -17.58% |
| 2021 Q4 | 5.51 Million USD | 7.92% |
| 2021 Q3 | 5.11 Million USD | -9.81% |
| 2020 Q2 | 6.5 Million USD | -9.21% |
| 2020 Q1 | 7.15 Million USD | 12.94% |
| 2020 Q4 | 6.08 Million USD | -29.45% |
| 2020 FY | 28.37 Million USD | -12.25% |
| 2020 Q3 | 8.63 Million USD | 32.78% |
| 2019 Q2 | 8.86 Million USD | -2.12% |
| 2019 FY | 32.33 Million USD | 19.9% |
| 2019 Q4 | 6.33 Million USD | -21.49% |
| 2019 Q3 | 8.07 Million USD | -8.94% |
| 2019 Q1 | 9.05 Million USD | 7.16% |
| 2018 Q4 | 8.45 Million USD | 31.97% |
| 2018 FY | 26.97 Million USD | 28.23% |
| 2018 Q3 | 6.4 Million USD | -0.48% |
| 2018 Q2 | 6.43 Million USD | 13.43% |
| 2018 Q1 | 5.67 Million USD | -7.38% |
| 2017 Q1 | 4.9 Million USD | 0.0% |
| 2017 Q2 | 4.66 Million USD | -4.95% |
| 2017 Q3 | 5.33 Million USD | 14.27% |
| 2017 Q4 | 6.12 Million USD | 14.91% |
| 2017 FY | 21.03 Million USD | 2.81% |
| 2016 FY | 20.46 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -3447.167% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -153.075% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 21.798% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 65.069% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -48.046% |
| Better Therapeutics, Inc. | 38.26 Million USD | 38.699% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 42.355% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -89.264% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 30.697% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 31.854% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 78.376% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -2262.489% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 28.028% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 50.044% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -1830.949% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -17.632% |
| Molecular Templates, Inc. | 63.09 Million USD | 62.824% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -68.358% |
| NexImmune, Inc. | 28.16 Million USD | 16.73% |
| Orgenesis Inc. | 45.75 Million USD | 48.74% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 8.547% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -31848.077% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -45.275% |
| Scopus BioPharma Inc. | 11.71 Million USD | -100.216% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 94.188% |
| Statera Biopharma, Inc. | 28.82 Million USD | 18.642% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -23.91% |
| Trevena, Inc. | 38.41 Million USD | 38.94% |
| Vaxxinity, Inc. | 56.05 Million USD | 58.154% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -2140.257% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 53.731% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -222.422% |